Jonathan Wadsley

11.8k total citations · 2 hit papers
89 papers, 2.3k citations indexed

About

Jonathan Wadsley is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jonathan Wadsley has authored 89 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 32 papers in Surgery and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jonathan Wadsley's work include Pancreatic and Hepatic Oncology Research (24 papers), Thyroid Cancer Diagnosis and Treatment (21 papers) and Cancer Genomics and Diagnostics (16 papers). Jonathan Wadsley is often cited by papers focused on Pancreatic and Hepatic Oncology Research (24 papers), Thyroid Cancer Diagnosis and Treatment (21 papers) and Cancer Genomics and Diagnostics (16 papers). Jonathan Wadsley collaborates with scholars based in United Kingdom, Germany and United States. Jonathan Wadsley's co-authors include David Cunningham, Stephen Falk, Gary Middleton, Ian Chau, Fareeda Y. Coxon, Wasat Mansoor, Justin S. Waters, John Bridgewater, Tom Crosby and Alicia Okines and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Jonathan Wadsley

83 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

2013 547 citations Ian Chau, David Cunningham et al. profile →
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

2013 405 citations John Bridgewater, Fareeda Y. Coxon et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Wadsley United Kingdom	20	1.3k	1.2k	992	320	257	89	2.3k
Daisuke Takahari Japan	29	1.7k 1.4×	1.8k 1.5×	845 0.9×	524 1.6×	55 0.2×	217	3.1k
C.J.H. van de Velde Netherlands	24	2.1k 1.6×	1.7k 1.4×	2.0k 2.0×	1.0k 3.2×	54 0.2×	52	4.1k
Inkeun Park South Korea	25	870 0.7×	665 0.5×	464 0.5×	170 0.5×	37 0.1×	107	1.7k
Margherita Nannini Italy	25	1.1k 0.9×	444 0.4×	509 0.5×	958 3.0×	39 0.2×	128	2.1k
Cristian Lolli Italy	19	761 0.6×	578 0.5×	263 0.3×	236 0.7×	49 0.2×	88	1.4k
Jean‐Marie Boher France	21	1.1k 0.9×	1.1k 0.9×	561 0.6×	26 0.1×	127 0.5×	100	2.1k
Jae Moon Bae South Korea	31	2.7k 2.1×	987 0.8×	1.4k 1.4×	1.3k 4.0×	29 0.1×	132	3.9k
J R Farndon United Kingdom	24	459 0.4×	790 0.6×	707 0.7×	56 0.2×	481 1.9×	58	2.2k
Tae Sung Sohn South Korea	34	3.2k 2.5×	1.1k 0.9×	1.7k 1.7×	1.5k 4.8×	32 0.1×	127	4.3k
Richard Quek Singapore	22	591 0.5×	735 0.6×	198 0.2×	162 0.5×	38 0.1×	64	1.5k

Countries citing papers authored by Jonathan Wadsley

Since Specialization

Citations

This map shows the geographic impact of Jonathan Wadsley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Wadsley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Wadsley more than expected).

Fields of papers citing papers by Jonathan Wadsley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Wadsley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Wadsley. The network helps show where Jonathan Wadsley may publish in the future.

Co-authorship network of co-authors of Jonathan Wadsley

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Wadsley. A scholar is included among the top collaborators of Jonathan Wadsley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Wadsley. Jonathan Wadsley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Croft, Julie, Neil Corrigan, A.J. Perry, et al.. (2025). NIFTy: near-infrared fluorescence (NIRF) imaging to prevent postsurgical hypoparathyroidism (PoSH) after thyroid surgery—a phase II/III pragmatic, multicentre randomised controlled trial protocol in patients undergoing a total or completion thyroidectomy. BMJ Open. 15(1). e092422–e092422. 2 indexed citations

Brose, Marcia S., Bruce Robinson, Lori J. Wirth, et al.. (2024). Comparative patient-reported tolerability (PRT): A multiplicity-controlled analysis of LIBRETTO-531, a randomized controlled trial (RCT) in medullary thyroid cancer (MTC).. Journal of Clinical Oncology. 42(16_suppl). 11111–11111. 3 indexed citations

Wadsley, Jonathan, Sabapathy P. Balasubramanian, Gitta Madani, et al.. (2023). Consensus statement on the management of incidentally discovered FDG avid thyroid nodules in patients being investigated for other cancers. Clinical Endocrinology. 101(5). 557–561. 5 indexed citations

Hackshaw, Allan, Kate Newbold, Matthew Beasley, et al.. (2023). 2212MO Major secondary outcomes in the multicentre noninferiority randomised trial IoN: Is ablative radioiodine necessary for low-risk differentiated thyroid cancer patients?. Annals of Oncology. 34. S1142–S1142. 3 indexed citations

Danson, Sarah, Fuschia M. Sirois, Jonathan Wadsley, et al.. (2023). Mental health burden for NHS healthcare staff during the COVID-19 pandemic: First results of a longitudinal survey. Heliyon. 9(3). e13765–e13765. 2 indexed citations

Brown, Malcolm, Dominic O’Connor, Richard Turkington, et al.. (2023). Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series. BMC Sports Science Medicine and Rehabilitation. 15(1). 116–116. 1 indexed citations

Ashley, Laura, Ian Kellar, Lisa Kidd, et al.. (2022). Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians. BMJ Open. 12(2). e060402–e060402. 3 indexed citations

Wadsley, Jonathan, Matthew Beasley, R. Chandler, et al.. (2022). Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK. Clinical Oncology. 35(1). 42–56. 8 indexed citations

Lamarca, Ángela, et al.. (2022). 54MO Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial. Annals of Oncology. 33. S564–S565. 5 indexed citations

10.

Wadsley, Jonathan, Matthew Beasley, Kate Garcez, et al.. (2022). Guidelines on the Use of Systemic Therapy in Patients with Advanced Thyroid Cancer. Clinical Oncology. 35(1). 57–64.

11.

Bull, M., et al.. (2020). A pragmatic assessment of the British Thyroid Association “U classification” of thyroid nodules with a focus on their follow-up. Clinical Radiology. 75(6). 466–473. 6 indexed citations

12.

Brown, Sarah, Andrew Hall, Hannah Buckley, et al.. (2019). Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC Cancer. 19(1). 582–582. 27 indexed citations

13.

Wadsley, Jonathan, Rebecca Gregory, Glenn Flux, et al.. (2017). SELIMETRY—a multicentre I-131 dosimetry trial: a clinical perspective. British Journal of Radiology. 90(1073). 20160637–20160637. 25 indexed citations

14.

Neoptolemos, John P., Paula Ghaneh, David Cunningham, et al.. (2016). ESPAC-4 : A Multicenter, International, Randomized Controlled Phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (GEM) and Capecitabine (CAP), Versus Monotherapy Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma. Pancreas. 45(10). 1529–1529. 2 indexed citations

15.

Ramage, John, Olusola Olusesan Faluyi, Andrea Frilling, et al.. (2016). UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE study. Annals of Oncology. 27. vi143–vi143. 1 indexed citations

16.

Neoptolemos, John P., Paula Ghaneh, Juan W. Valle, et al.. (2016). ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 34(15_suppl). LBA4006–LBA4006. 4 indexed citations

17.

Danson, Sarah, Christine Rowland, Richard Rowe, et al.. (2015). The relationship between smoking and quality of life in advanced lung cancer patients: a prospective longitudinal study. Supportive Care in Cancer. 24(4). 1507–1516. 34 indexed citations

18.

Edafe, Ovie, Jonathan Wadsley, Barney Harrison, & Sabapathy P. Balasubramanian. (2014). Treatment related morbidity in differentiated thyroid cancer–a survey of clinicians. Thyroid Research. 7(1). 3–3. 6 indexed citations

19.

Neoptolemos, John P., William Greenhalf, Trevor F. Cox, et al.. (2014). Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial.. Journal of Clinical Oncology. 32(15_suppl). 4121–4121. 6 indexed citations

20.

Middleton, Gary, Sarah Brown, Catherine Lowe, et al.. (2013). A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). European Journal of Cancer. 49(16). 3507–3516. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact